Huge opportunities remain for premium-priced tyrosine kinase inhibitors in PAH: Report
The pulmonary arterial hypertension (PAH) space, which is currently burdened by significant unmet need, could benefit substantially from a class of drugs known as tyrosine kinase inhibitors (TKIs), which may aid development of a disease-modifying drug.
According to an analyst with research and consulting firm GlobalData, currently, there are 12 marketed therapies for the treatment of PAH from companies including Actelion (SIX: ATLN), GlaxoSmithKline (LSE: GSK), United Therapeutics, Bayer (BAYN: DE), Pfizer (NYSE: PFE), and Gilead Sciences (Nasdaq: GILD).
Lakshmi Dharmarajan, GlobalData’s senior analyst covering cardiovascular and metabolic disorders, says that manufacturing a drug using TKIs could present a significant opportunity for pharmaceutical companies, with the prospect of commanding a high premium over currently existing treatments, which already range in cost from $50,000-$150,000 per year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze